- Home
- AEVA vs PBYI Comparison
AEVA vs PBYI Comparison
Compare AEVA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- PBYI
- Stock Information
- Founded
- AEVA 2019
- PBYI 2010
- Country
- AEVA United States
- PBYI United States
- Employees
- AEVA N/A
- PBYI N/A
- Industry
- AEVA Auto Parts:O.E.M.
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- PBYI Health Care
- Exchange
- AEVA Nasdaq
- PBYI Nasdaq
- Market Cap
- AEVA 177.0M
- PBYI 176.1M
- IPO Year
- AEVA N/A
- PBYI N/A
- Fundamental
- Price
- AEVA $2.72
- PBYI $2.51
- Analyst Decision
- AEVA Buy
- PBYI Strong Buy
- Analyst Count
- AEVA 5
- PBYI 1
- Target Price
- AEVA $10.03
- PBYI $7.00
- AVG Volume (30 Days)
- AEVA 262.6K
- PBYI 352.8K
- Earning Date
- AEVA 11-06-2024
- PBYI 10-31-2024
- Dividend Yield
- AEVA N/A
- PBYI N/A
- EPS Growth
- AEVA N/A
- PBYI N/A
- EPS
- AEVA N/A
- PBYI 0.18
- Revenue
- AEVA $6,540,000.00
- PBYI $219,143,000.00
- Revenue This Year
- AEVA $109.97
- PBYI N/A
- Revenue Next Year
- AEVA $136.96
- PBYI N/A
- P/E Ratio
- AEVA N/A
- PBYI $13.95
- Revenue Growth
- AEVA 89.40
- PBYI N/A
- 52 Week Low
- AEVA $2.20
- PBYI $2.13
- 52 Week High
- AEVA $7.25
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- AEVA 46.84
- PBYI 42.40
- Support Level
- AEVA $2.36
- PBYI $2.23
- Resistance Level
- AEVA $2.60
- PBYI $2.42
- Average True Range (ATR)
- AEVA 0.23
- PBYI 0.16
- MACD
- AEVA -0.03
- PBYI 0.03
- Stochastic Oscillator
- AEVA 36.36
- PBYI 59.57
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.